
|Articles|December 3, 2007
FDA approves Alcon steroid
The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.
Advertisement
The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.
Triesence injectable suspension, the active ingredient of which is triamcinolone acetonide, is indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, in addition to being used for visualization during vitrectomy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Why ST-100 is expanding from dry eye into corneal wound healing
2
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
3
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
4
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
5
















